Combined Allergic Rhinitis and Asthma Syndrome
Conditions
Keywords
CARAS, EBC, Biomarkers, Combination of disease and evidence
Brief summary
To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.
Interventions
OTHERquestionnaire survey
subjects fill out questionnaires
Sponsors
Henan University of Traditional Chinese Medicine
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria; * Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence; * Age 18 to 80 years; * Voluntarily accepted the study and signed an informed consent form; * Not participated in other clinical studies within 1 month before enrollment.
Exclusion criteria
* Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose; * Patients who are participating in other drug trials; * Patients with a combination of other serious systemic diseases; * Pregnant or lactating women; * Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eosinophil cationic proteins (ECP) | Basline | Airway inflammation will be assessed using the ECP. |
| Immunoglobulin E (IgE) | Basline | Airway inflammation will be assessed using the IgE. |
| Interleukin-2、4、5、13 (IL-2、4、5、13) | Basline | Airway inflammation will be assessed using the IL-2、4、5、13. |
| Interferon-γ (IFN-γ) | Basline | Airway inflammation will be assessed using the IFN-γ. |
| Tumor necrosis factor-β (TNF-β) | Basline | Airway inflammation will be assessed using the TNF-β. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fractional exhaled nitric oxide (FeNO) | Basline | Higher FeNO values indicate higher airway inflammation. |
| Forced expiratory volume in one second (FEV1) | Basline | Lung function will be assessed using the FEV1. |
| Forced vital capacity (FVC) | Basline | Lung function will be assessed using the FEV1. |
| FVC as the percentage of the predicted value (FVC%) | Basline | Lung function will be assessed using the FVC%. |
| Forced expiratory volume in one second / forced vital capacity (FEV1/FVC) | Basline | Lung function will be assessed using the FEV1/FVC. |
Countries
China
Contacts
Primary ContactYang Xie
Outcome results
None listed